{"id":12735,"date":"2020-08-06T08:51:31","date_gmt":"2020-08-06T06:51:31","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/?post_type=gco_media&p=12735"},"modified":"2020-08-26T09:03:53","modified_gmt":"2020-08-26T07:03:53","slug":"modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation","status":"publish","type":"gco_media","link":"https:\/\/www.izb-online.de\/en\/mediathek\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\/","title":{"rendered":"MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]15.06.2020[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner width=”2\/3″ offset=”vc_col-lg-6 vc_col-md-6″][vc_column_text]<\/p>\n


\nDownload PDF<\/span><\/a><\/div>\n

[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/3″ offset=”vc_col-lg-6 vc_col-md-6″][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]<\/p>\n

WENDELSHEIM, Germany, August 5, 2020 <\/span>\u2013 MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today announced the successful completion of its first clinical trial of anle138b (<\/span>NCT04208152<\/span><\/strong>) in healthy volunteers. The Company\u2019s lead candidate, which was administered in doses of up to 300 mg daily, demonstrated excellent safety and tolerability profiles at all dose levels and reached significantly higher plasma levels in humans than those required for full therapeutic efficacy in animal models. Anle138b was initially developed for the treatment of Multiple System Atrophy (MSA) and has the potential to be applied to other synucleinopathies, such as Parkinson’s disease. Based on the positive Phase 1 study results, MODAG was also able to obtain additional funding of USD 1.4 million from The Michael J. Fox Foundation for Parkinson’s Research.<\/strong> <\/span><\/p>\n

\u201cThe successful completion of our first clinical trial with anle138b is an important step toward beginning further evaluation in neurodegenerative diseases and underscores our expertise in drug development,\u201d commented Dr. Torsten Matthias, CEO of MODAG. “The fact that we were able to carry out this study in a timely manner despite the COVID-19 pandemic, is largely due to the tireless efforts and commitment of the MODAG team. I would also like to thank our Phase 1 study partners, Quotient Sciences, Aptuit and Granzer Consulting.\u201d<\/p>\n

Professor Armin Giese, CSO of MODAG, continued, \u201cAnle138b is a small molecule that specifically binds to toxic oligomeric structures of alpha-synuclein, the core aggregating protein in Parkinson’s disease. This prevents the formation of new oligomers and thereby blocks the disease-specific aggregation process from advancing. In the recently completed Phase 1 study, safety, tolerability and pharmacokinetic properties of anle138b known from animal models were confirmed in humans. Already at a 100 mg dose-level, anle138b plasma levels that were significantly above the threshold dose effective in animal experiments could be achieved. Furthermore, no therapy-specific side effects were observed. The plasma half-life of anle138b after oral administration in capsule form was about 12 hours, which is ideal for this application. Furthermore, it could be shown that the uptake of the substance was not significantly altered by parallel food intake.\u201d<\/p>\n

Professor Johannes Levin, CMO of MODAG, added: \u201cThe data from this Phase 1 study will serve as the foundation for the further clinical development of our lead candidate. We are diligently working on the next step: a first-in-patient study investigating safety, tolerability and pharmacokinetics in Parkinson’s patients which is planned to start by the end of this year. MODAG already received a $1.26 million grant from The Michael J. Fox Foundation in 2015 toward pre-clinical optimization of anle138b and biomarker assay development and now the foundation will support this first-in-patient study. The reviewers of The Michael J. Fox Foundation are among the world’s leading experts on Parkinson’s disease, so the funding for this study from this highly recognized organization adds further validation to our approach and its potential. In my clinical work with MSA and Parkinson\u2019s patients, I am confronted with the urgent need for disease-modifying treatments on a daily basis. Thus, I am pleased that we have made such rapid progress towards the first potential tests in patients.\u201d<\/p>\n

Following the first-in-patient study, MODAG plans to conduct long-term clinical trials investigating the efficacy of anle138b in MSA and Parkinson\u2019s disease patients. These studies are anticipated to begin at the end of 2021.<\/p>\n

About anle138b <\/strong><\/p>\n

MODAG\u2019s lead candidate, anle138b, is a small molecule compound that specifically binds toxic oligomeric structures of alpha-synuclein, the core aggregating protein in Parkinsonian disorders. Through the binding, anle138b dissolves toxic oligomers and prevents new oligomers from forming, addressing the diseases at the core. Pre-clinical animal model studies in Parkinson\u2019s disease and MSA have demonstrated the ability to halt disease progression and alleviate symptoms in vivo<\/em>, effectively preventing further damage by stopping the accumulation of pathological protein aggregates in the brain. In contrast to antibodies, anle138b can be administered orally, efficiently passing the blood-brain-barrier, while directly acting on toxic intracellular oligomers.<\/p>\n

About MODAG <\/strong><\/p>\n

MODAG, a privately held German biotech company, aims to provide a novel approach for treating neurodegenerative diseases by combining targeted small molecule therapeutics with the right diagnostic tools. Our first objective is to demonstrate clinical proof-of-concept with our lead compound anle138b in Multiple System Atrophy (MSA) and Parkinson\u2019s disease, seeking to halt the progression and provide a first disease-modifying therapeutic. This success will allow us to apply our technology to similar diseases with protein aggregation including Alzheimer\u2019s disease and tauopathies such as PSP, with the goal of dissolving disease-related intra-cellular oligomers, thereby reducing their toxic properties. The company was founded based on research conducted by scientists at the Ludwig Maximilian University of Munich and the Max-Planck-Institute for Biophysical Chemistry in G\u00f6ttingen and has been supported by grants from leading patient organizations including The Michael J. Fox Foundation for Parkinson\u2019s Research, the Cure Parkinson\u2019s Trust, and Parkinson\u2019s UK. For more information see www.modag.net<\/a><\/p>\n

Contact Information<\/strong><\/p>\n

For MODAG:
\n<\/strong>Dr. Torsten Matthias, CEO
\nWebsite: www.modag.net
\nE-Mail: info@modag.net
\nPhone: +49 6734 96 228000<\/p>\n

For Media Inquiries:
\n<\/strong>Trophic Communications
\nStephanie May or Valeria Fisher
\nE-Mail: may@trophic.eu or fisher@trophic.eu
\nPhone: +49 171 185 56 82 or +49 175 804 18 16[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"featured_media":1644,"template":"","meta":{"_links_to":"","_links_to_target":""},"media-categories":[7432,7431],"class_list":["post-12735","gco_media","type-gco_media","status-publish","has-post-thumbnail","hentry","media-categories-press-release","media-categories-press-release-izb-martinsried"],"yoast_head":"\nMODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.izb-online.de\/en\/mediathek\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation\" \/>\n<meta property=\"og:description\" content=\"MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.izb-online.de\/en\/mediathek\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\/\" \/>\n<meta property=\"og:site_name\" content=\"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\" \/>\n<meta property=\"article:modified_time\" content=\"2020-08-26T07:03:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/Modag_Start-Up-im-IZB-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"80\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\\\/\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\\\/\",\"name\":\"MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Modag_Start-Up-im-IZB-1.jpg\",\"datePublished\":\"2020-08-06T06:51:31+00:00\",\"dateModified\":\"2020-08-26T07:03:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Modag_Start-Up-im-IZB-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Modag_Start-Up-im-IZB-1.jpg\",\"width\":400,\"height\":80},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PRESS RELEASE\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/media-library\\\/press-release\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Press release standard\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/media-library\\\/press-release\\\/press-release-izb-martinsried\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\",\"name\":\"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"description\":\"Innovations- und Gr\u00fcnderzentrum Biotechnologie\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\",\"name\":\"F\u00f6rdergesellschaft IZB mbH\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/izb-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/izb-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"F\u00f6rdergesellschaft IZB mbH\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.izb-online.de\/en\/mediathek\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\/","og_locale":"en_US","og_type":"article","og_title":"MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation","og_description":"MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation","og_url":"https:\/\/www.izb-online.de\/en\/mediathek\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\/","og_site_name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","article_modified_time":"2020-08-26T07:03:53+00:00","og_image":[{"width":400,"height":80,"url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/Modag_Start-Up-im-IZB-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.izb-online.de\/en\/mediathek\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\/","url":"https:\/\/www.izb-online.de\/en\/mediathek\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\/","name":"MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","isPartOf":{"@id":"https:\/\/www.izb-online.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.izb-online.de\/en\/mediathek\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\/#primaryimage"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/mediathek\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/Modag_Start-Up-im-IZB-1.jpg","datePublished":"2020-08-06T06:51:31+00:00","dateModified":"2020-08-26T07:03:53+00:00","breadcrumb":{"@id":"https:\/\/www.izb-online.de\/en\/mediathek\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.izb-online.de\/en\/mediathek\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.izb-online.de\/en\/mediathek\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\/#primaryimage","url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/Modag_Start-Up-im-IZB-1.jpg","contentUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/Modag_Start-Up-im-IZB-1.jpg","width":400,"height":80},{"@type":"BreadcrumbList","@id":"https:\/\/www.izb-online.de\/en\/mediathek\/modag-successfully-completes-phase-1-study-of-their-lead-candidate-anle138b-and-receives-additional-usd-1-4-million-from-michael-j-fox-foundation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.izb-online.de\/en\/"},{"@type":"ListItem","position":2,"name":"PRESS RELEASE","item":"https:\/\/www.izb-online.de\/en\/media-library\/press-release\/"},{"@type":"ListItem","position":3,"name":"Press release standard","item":"https:\/\/www.izb-online.de\/en\/media-library\/press-release\/press-release-izb-martinsried\/"},{"@type":"ListItem","position":4,"name":"MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation"}]},{"@type":"WebSite","@id":"https:\/\/www.izb-online.de\/en\/#website","url":"https:\/\/www.izb-online.de\/en\/","name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","description":"Innovations- und Gr\u00fcnderzentrum Biotechnologie","publisher":{"@id":"https:\/\/www.izb-online.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.izb-online.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.izb-online.de\/en\/#organization","name":"F\u00f6rdergesellschaft IZB mbH","url":"https:\/\/www.izb-online.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/06\/izb-logo.svg","contentUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/06\/izb-logo.svg","width":1,"height":1,"caption":"F\u00f6rdergesellschaft IZB mbH"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/gco_media\/12735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/gco_media"}],"about":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/types\/gco_media"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media\/1644"}],"wp:attachment":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media?parent=12735"}],"wp:term":[{"taxonomy":"media-categories","embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media-categories?post=12735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}